October 25 is MDS World Awareness Day. We stand with everyone living with blood cancer — this month and every day.

Publications & Presentations

Advancing scientific understanding from research to real-world evidence.
Every study contributes to a deeper understanding of blood cancer and the potential for new treatment approaches. Through clinical trials, real-world evidence, investigator-sponsored research, and scientific collaboration, Geron is committed to generating evidence that may help advance science, inform clinical practice, and improve outcomes for people living with blood cancer.

Explore our scientific publications and presentations:

This page may contain non-exhaustive scientific information about post-hoc, exploratory, subgroup analyses, or uses that have not yet been approved by regulatory authorities. The information is provided for educational and scientific exchange purposes only, and does not suggest products should be used in a manner not consistent with their respective label approved by the regulatory authorities, which may differ by geography. Any publication reflects the state of knowledge at the time it was published. The information is not medical advice and cannot replace the independent medical judgement of a healthcare professional.

Journal articles

Telomerase Inhibition With Imetelstat in Patients With Lower-Risk Myelodysplastic Syndromes: Integrating Molecular Findings, Cytopenias, and Clinical Outcomes

DGHO

October 9, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Durable Clinical Outcomes With Imetelstat (IME) in Korean Patients (Pts) With Lower-Risk (LR)-MDS

JSH

October 9, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Real-World Experience With Imetelstat in Lower-Risk Myelodysplastic Syndromes: Insights From United States Claims Data

JSH

October 9, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Real-World Data

Combining the Telomerase Inhibitor Imetelstat with the BCL-2 Inhibitor Venetoclax Enhances Apoptosis and Improves Survival in Acute Myeloid Leukemia Cellular and Animal Models

Journal of Clinical Medicine

September 23, 2026
Acute Myeloid Leukemia (AML)Preclinical Data

Increased duration of time without transfusion reliance with imetelstat vs placebo in the phase 3 IMerge trial

Blood Neoplasia

April 16, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Association between treatment-emergent cytopenias and clinical responses to imetelstat in lower-risk myelodysplastic syndromes

Blood Cancer Journal

April 7, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Clinical outcomes and safety in patients with lower-risk myelodysplastic syndromes treated with imetelstat: Substudy of the phase 3 IMerge trial

British Journal of Haematology

February 1, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge study

Haematologica

January 22, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat

Nature Leukemia

January 12, 2026
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Effect of prior therapy on the clinical activity of imetelstat in patients with transfusion-dependent, ESA-relapsed or -refractory/-ineligible LR-MDS

Blood Cancer Journal

December 31, 2025
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

No Effect of Immunogenicity on Pharmacokinetics, Efficacy, and Safety of the Oligonucleotide Telomerase Inhibitor Imetelstat in Lower-Risk Myelodysplastic Syndromes

Clinical and Translational Science

December 14, 2025
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Plain language summary of IMerge, a Phase 3 studyof imetelstat versus placebo in people with lower-risk myelodysplastic syndromes and anemia

Future Oncology

October 12, 2025
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Conference presentations

Imetelstat-Mediated Alterations in Lipid Metabolism to Induce Ferroptosis As Therapeutic Strategy for Acute Myeloid Leukemia

ASH 2022

December 5, 2022
Acute Myeloid Leukemia (AML)Preclinical Data

Imetelstat Achieved Prolonged, Continuous Transfusion Independence in Patients With Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory to Erythropoiesis Stimulating Agents Within the IMerge Phase 2 Study

Longer follow-up data from the Phase 2 study in lower risk myelodysplastic syndromes (MDS)

ASH 2022

December 5, 2022
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Clinical and biological characterization of Low Risk MDS patients according to Ring Sideroblasts (RS). Comparison between the 3 subgroups in WHO2017 classification. Study from the Spanish MDS registry

ASH 2021

December 5, 2021
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Efficacy of Imetelstat is Independent of Molecular Subtypes in Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESA)

EHA 2021

June 12, 2021
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Imetelstat Demonstrates an Acceptable Safety Profile in Myeloid Malignancies

EHA 2021

June 12, 2021
Clinical Data

Treatment with Imetelstat Provides Durable Transfusion Independence (TI) in Heavily Transfused Non-del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs)

ASH 2020

December 5, 2020
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

IMerge: A Phase 3 Study to Evaluate Imetelstat in Transfusion-Dependent Subjects with IPSS Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) that is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

ASH 2020

December 5, 2020
Lower-risk Myelodysplastic Syndromes (LR-MDS)Clinical Data

Potential Disease-Modifying Activity of Imetelstat Demonstrated By Reduction in Cytogenetically Abnormal Clones and Mutation Burden Leads to Clinical Benefits in Relapsed/Refractory Myelofibrosis Patients

ASH 2020

December 5, 2020
Myelofibrosis (MF)Clinical Data

Telomerase Activity, Telomere Length and hTERT Expression Correlate with Clinical Outcomes in Higher-Risk Myelofibrosis (MF) Relapsed/Refractory (R/R) to Janus Kinase Inhibitor Treated with Imetelstat

ASH 2020

December 5, 2020
Myelofibrosis (MF)Clinical Data

Favorable Overall Survival with Imetelstat Treatment Correlates with Other Clinical Benefits in Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor

ASH 2020

December 5, 2020
Myelofibrosis (MF)Clinical Data

Correlation Analyses of Imetelstat Exposure with Pharmacodynamic Effect, Efficacy and Safety in a Phase 2 Study in Patients with Higher-risk Myelofibrosis Refractory to Janus Kinase Inhibitor Identified an Optimal Dosing Regimen for Phase 3 Study

ASH 2020

December 5, 2020
Myelofibrosis (MF)Clinical Data

Imetelstat Treatment Results in Clinical Benefits, Including Improved Overall Survival, in Patients with Higher-Risk Triple Negative Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitors (JAKi)

ASH 2020

December 5, 2020
Myelofibrosis (MF)Clinical Data